The US State of California is set to be the location for the first vending machines selling marijuana to patients with specific health conditions. According to a report by the UK broadcaster, the BBC, patients will be required to provide a prescription, have fingerprints and a photograph taken before being allowed to use one of the two first machines in the state.
The legality of the operation is controversial. On the one hand, 11 US states have authorized medical cannabinoid use, often by a popular referendum. However, the federal government claims that it has jurisdiction, under the 1970 Controlled Substances Act. Four cannabinoid drugs have been developed: Marinol (dronabinol from Solvay); nabilone; Sativex (a cannabis-based oromuscosal spray from GW Pharma); and rimonabant (Sanofi-Aventis' Acomplia brand for obesity).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze